164 related articles for article (PubMed ID: 35970525)
41. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
Front Immunol; 2022; 13():879266. PubMed ID: 35603153
[TBL] [Abstract][Full Text] [Related]
42. Rheumatoid Arthritis Complicated with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Interstitial Pneumonia.
Matsumoto H; Sato S; Fujita Y; Yashiro-Furuya M; Matsuoka N; Asano T; Kobayashi H; Watanabe H; Migita K
Intern Med; 2019 Mar; 58(5):737-742. PubMed ID: 30333415
[TBL] [Abstract][Full Text] [Related]
43. Relevance of leukaemia inhibitory factor to anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease.
Ichimura Y; Ikei H; Konishi R; Zeniya M; Okai T; Nomura T; Negishi K; Okiyama N
Rheumatology (Oxford); 2023 Jun; 62(6):2267-2271. PubMed ID: 36326445
[TBL] [Abstract][Full Text] [Related]
44. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Matsuda KM; Yoshizaki A; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Sato S
J Dermatol; 2020 May; 47(5):483-489. PubMed ID: 32096271
[TBL] [Abstract][Full Text] [Related]
45. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.
Mehta AA; Paul T; Cb M; Haridas N
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33910791
[TBL] [Abstract][Full Text] [Related]
46. Clinical risk factors in patients with interstitial lung disease associated with anti-MDA5 autoantibodies.
Ramos-Martinez E; Rodríguez-Vega EA; Rivera-Matias PA; Falfán-Valencia R; Pérez-Rubio G; Mejia M; González-Pérez MI; Buendia-Roldán I; Mateos-Toledo HN; Serrano JR
Med Clin (Barc); 2023 Dec; 161(12):515-522. PubMed ID: 37567825
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment.
Shirakashi M; Nakashima R; Tsuji H; Tanizawa K; Handa T; Hosono Y; Akizuki S; Murakami K; Hashimoto M; Yoshifuji H; Ohmura K; Mimori T
Rheumatology (Oxford); 2020 Nov; 59(11):3284-3292. PubMed ID: 32276271
[TBL] [Abstract][Full Text] [Related]
48. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
Yamaguchi K; Yamaguchi A; Kashiwagi C; Sawada Y; Taguchi K; Umetsu K; Oshima K; Uchida M; Suzuki M; Kono S; Takemura M; Masubuchi H; Kitahara S; Hara K; Maeno T; Motegi SI; Muro Y; Sakairi T; Hisada T; Kurabayashi M
Respir Med; 2018 Jul; 140():1-5. PubMed ID: 29957268
[TBL] [Abstract][Full Text] [Related]
49. Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis.
So H; Wong VTL; Lao VWN; Pang HT; Yip RML
Clin Rheumatol; 2018 Jul; 37(7):1983-1989. PubMed ID: 29713969
[TBL] [Abstract][Full Text] [Related]
50. Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease.
Gui X; Li W; Yu Y; Zhao T; Jin Z; Meng K; Wang R; Shi S; Yu M; Ma M; Chen L; Luan W; Xin X; Qiu Y; Qiu X; Zhang Y; Cao M; Cao M; Dai J; Cai H; Huang M; Xiao Y
Front Immunol; 2022; 13():978708. PubMed ID: 36211445
[TBL] [Abstract][Full Text] [Related]
51. Cytokeratin 19 fragment is associated with severity and poor prognosis of interstitial lung disease in anti-MDA5 antibody-positive dermatomyositis.
Gui X; Ma M; Ding J; Shi S; Xin X; Qiu X; Zhang Y; Qiu Y; Cao M; Huang M; Cao M; Dai J; Cai H; Xiao Y
Rheumatology (Oxford); 2021 Aug; 60(8):3913-3922. PubMed ID: 33501503
[TBL] [Abstract][Full Text] [Related]
52. Anti-MDA5 positive dermatomyositis complicated with rapidly progressive interstitial lung disease - a case report.
De Backer E; Gremonprez F; Brusselle G; Depuydt P; Van Dorpe J; Van Haverbeke C; Goeminne PC; Derom E
Acta Clin Belg; 2018 Dec; 73(6):413-417. PubMed ID: 29287518
[TBL] [Abstract][Full Text] [Related]
53. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment.
Koichi Y; Aya Y; Megumi U; Shunichi K; Masafumi S; Hiroaki M; Masahiko K; Shinsuke K; Manabu U; Kenichiro H; Fumiaki A; Nozomi A; Toshitaka M; Masayoshi Y; Chikako K; Yoshinao M; Tatsuo S; Masahiko K
Mod Rheumatol; 2017 May; 27(3):536-540. PubMed ID: 25698373
[TBL] [Abstract][Full Text] [Related]
54. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review.
McPherson M; Economidou S; Liampas A; Zis P; Parperis K
Semin Arthritis Rheum; 2022 Apr; 53():151959. PubMed ID: 35134633
[TBL] [Abstract][Full Text] [Related]
55. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
56. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
Gono T; Kawaguchi Y; Satoh T; Kuwana M; Katsumata Y; Takagi K; Masuda I; Tochimoto A; Baba S; Okamoto Y; Ota Y; Yamanaka H
Rheumatology (Oxford); 2010 Sep; 49(9):1713-9. PubMed ID: 20498012
[TBL] [Abstract][Full Text] [Related]
57. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
Horiike Y; Suzuki Y; Fujisawa T; Yasui H; Karayama M; Hozumi H; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Ogawa N; Suda T
Rheumatology (Oxford); 2019 Dec; 58(12):2143-2152. PubMed ID: 31143953
[TBL] [Abstract][Full Text] [Related]
58. Management of Myositis-Associated Interstitial Lung Disease.
Fujisawa T
Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33916864
[TBL] [Abstract][Full Text] [Related]
59. Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease.
Gao Y; Zhao Q; Xie M; Yan X; Li Y; Zhang X; Wu H; Dai J; Cao M; Cai H
Cytokine; 2020 Nov; 135():155209. PubMed ID: 32738770
[TBL] [Abstract][Full Text] [Related]
60. Antimelanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease After Vaccination With COVID-19 mRNA Vaccines.
Kitajima T; Funauchi A; Nakajima T; Marumo S; Imura Y; Fukui M
J Rheumatol; 2022 Oct; 49(10):1158-1162. PubMed ID: 35705246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
